Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Leukemia (35)
Blood Cancer Journal (19)
Nature Communications (13)
British Journal of Cancer (3)
Nature Genetics (3)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (62)
Correspondence (10)
Amendments and Corrections (5)
Reviews (5)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Cell biology
Chemical biology
Diseases
Genetics
Health care
Immunology
Medical research
Molecular biology
Molecular medicine
Oncology
Risk factors

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–50 of 82 results

Advanced filters: Author: Hartmut Goldschmidt Clear advanced filters

Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy

Understanding the immunological underpinnings of long-term survival in cancer is of high interest. Here, authors dissect the immune parameters of multiple myeloma long-term survivors following a single line of therapy longitudinally, and find sustained changes, including inflammation and impaired immune function.

Raphael Lutz
Florian Grünschläger
Simon Haas
ResearchOpen Access29 Nov 2024
Nature Communications

Volume: 15, P: 1-18
Publisher Correction: Predicting progression events in multiple myeloma from routine blood work

Maximilian Ferle
Nora Grieb
Maximilian Merz
Amendments and CorrectionsOpen Access28 May 2025
npj Digital Medicine

Volume: 8, P: 1
Predicting progression events in multiple myeloma from routine blood work

Maximilian Ferle
Nora Grieb
Maximilian Merz
ResearchOpen Access30 Apr 2025
npj Digital Medicine

Volume: 8, P: 1-15
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma

The prognosis of multiple myeloma patients varies widely. Here, to identify genetic factors associated with differing prognoses, the authors carried out a meta-analysis of four genome-wide association studies and identified a risk variant associated with survival interval.

David C. Johnson
Niels Weinhold
Gareth J. Morgan
ResearchOpen Access08 Jan 2016
Nature Communications

Volume: 7, P: 1-7
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma

Previous genome-wide association studies have identified loci associated with the risk of multiple myeloma. Here, the authors present a meta-analysis of six genome wide association studies of the disease and identify eight new loci; functional studies identify genes as candidates for the basis of these associations.

Jonathan S. Mitchell
Ni Li
Richard S. Houlston
ResearchOpen Access01 Jul 2016
Nature Communications

Volume: 7, P: 1-9
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Multiple myeloma is a cancer of the plasma cells, and the complete aetiology of the disease is still unclear. Here the authors perform an additional GWAS analysis followed by a meta-analysis with existing GWAS and replication genotyping and identify 6 novel risk loci and utilise gene expression, epigenetic profiling and in situ Hi-C data to further our understanding of MM susceptibility.

Molly Went
Amit Sud
Stephen N. Thibodeau
ResearchOpen Access13 Sept 2018
Nature Communications

Volume: 9, P: 1-10
Deciphering the genetics and mechanisms of predisposition to multiple myeloma

Multiple myeloma (MM) is an incurable blood malignancy. Here, the authors report 35 MM risk loci and two causal mechanisms for genetic MM risk: longer telomeres and elevated plasma B-cell maturation antigen (BCMA) and interleukin−5 receptor alpha (IL5RA) levels.

Molly Went
Laura Duran-Lozano
Björn Nilsson
ResearchOpen Access05 Aug 2024
Nature Communications

Volume: 15, P: 1-15
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

Elias K. Mai
Kaya Miah
Hartmut Goldschmidt
Amendments and CorrectionsOpen Access16 Nov 2021
Leukemia

Volume: 35, P: 3636
Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance

Kosima Zuern
Thomas Hielscher
Elias K. Mai
ResearchOpen Access27 Aug 2024
Blood Cancer Journal

Volume: 14, P: 1-7
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis

Fengjuan Fan
Stefano Malvestiti
Klaus Podar
Amendments and CorrectionsOpen Access06 Sept 2021
Leukemia

Volume: 35, P: 3628
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

Myelomagenesis progresses through well-defined pre-malignant states. Here, using single-cell RNA sequencing and T cell receptor repertoire analysis of bone marrow T cells in patients at different stages of myelomagenesis, the authors identify large clonotypic expansions characterized by the expression of multiple immune checkpoints.

Cirino Botta
Cristina Perez
Bruno Paiva
ResearchOpen Access20 Sept 2023
Nature Communications

Volume: 14, P: 1-15
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

Richard Houlston, Kari Hemminki and colleagues report a meta-analysis of genome-wide association studies of multiple myeloma and identify a variant in the CCDN1 gene that influences risk for developing a specific tumor karyotype with the t(11;14)(q13;q32) translocation.

Niels Weinhold
David C Johnson
Kari Hemminki
Research17 Mar 2013
Nature Genetics

Volume: 45, P: 522-525
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level

The spatial architecture of multiple myeloma remains to be explored. Here, the authors perform bulk and single cell sequencing for samples from newly diagnosed patients and reveal gene signatures associated with focal lesions and spatial heterogeneity in the tumour microenvironment.

Lukas John
Alexandra M. Poos
Niels Weinhold
ResearchOpen Access17 Aug 2023
Nature Communications

Volume: 14, P: 1-17
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression

Genome wide association studies have identified multiple risk loci for multiple myeloma. Here, the authors show that the expression of CDCA7Lis associated with patient survival and expression of the gene is influenced by a risk variant at 7p15.3, which creates a transcription factor binding site for IRF4.

Ni Li
David C. Johnson
Richard S. Houlston
ResearchOpen Access24 Nov 2016
Nature Communications

Volume: 7, P: 1-9
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics

Relapsed/refractory multiple myeloma (RRMM) is characterized by a remarkable heterogeneity and high drug resistance. Here, the authors analyse RRMM samples by single-cell RNA-sequencing, revealing molecular features associated with high-risk chromosomal 1q-gain and changes in the tumor microenvironment.

Stephan M. Tirier
Jan-Philipp Mallm
Karsten Rippe
ResearchOpen Access29 Nov 2021
Nature Communications

Volume: 12, P: 1-16
Functional dissection of inherited non-coding variation influencing multiple myeloma risk

The causality and functional roles of disease-associated variants revealed by genome-wide association studies (GWAS) are mostly unexplored. Here the authors identify putative causal variants in multiple myeloma and find their association with gene expression and chromatin accessibility.

Ram Ajore
Abhishek Niroula
Björn Nilsson
ResearchOpen Access10 Jan 2022
Nature Communications

Volume: 13, P: 1-15
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

Carlos Fernández de Larrea
Robert Kyle
Maria Victoria Mateos
ResearchOpen Access02 Dec 2021
Blood Cancer Journal

Volume: 11, P: 1-5
CD8⁺ CD28⁻ regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Katharina Kriegsmann
Gigi Nu Hoang Quy Ton
Michael Hundemer
ResearchOpen Access03 Jun 2024
Leukemia

Volume: 38, P: 1621-1625
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression

ELL2 was recently discovered as a susceptibility gene for multiple myeloma (MM). Here, they show that the MM risk allele lowers ELL2 expression in plasma cells, that it also upregulates gene sets related to ribosome biogenesis, and that one of the linked variants reduces binding of MAFF/G/K family transcription factors.

Mina Ali
Ram Ajore
Björn Nilsson
ResearchOpen Access25 Apr 2018
Nature Communications

Volume: 9, P: 1-9
Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk

Ram Ajore
Abhishek Niroula
Björn Nilsson
Amendments and CorrectionsOpen Access13 Dec 2022
Nature Communications

Volume: 13, P: 1
Sensitive digital quantification of DNA methylation in clinical samples

Gene-specific changes in DNA methylation are promising biomarkers, but sensitive quantitative detection of these epigenetic marks remains challenging. Li et al. adapt the so-called BEAMing technology to enable high-throughput digital quantification of gene methylation in clinical samples.

Meng Li
Wei-dong Chen
Bert Vogelstein
Research16 Aug 2009
Nature Biotechnology

Volume: 27, P: 858-863
The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications

Kari Hemminki
Asta Försti
Xinjun Li
ResearchOpen Access22 Jun 2016
Scientific Reports

Volume: 6, P: 1-7
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk

Richard Houlston and colleagues report a genome-wide association study of multiple myeloma and identify four loci associated with susceptibility to this malignancy.

Daniel Chubb
Niels Weinhold
Hartmut Goldschmidt
Research18 Aug 2013
Nature Genetics

Volume: 45, P: 1221-1225
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Hartmut Goldschmidt
Marc-Andrea Baertsch
Katja Weisel
Research21 Jul 2020
Leukemia

Volume: 35, P: 1134-1144
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

Hartmut Goldschmidt
Meletios A. Dimopoulos
Maria Victoria Mateos
ResearchOpen Access23 Apr 2020
Leukemia

Volume: 34, P: 3019-3027
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

Thierry Facon
Philippe Moreau
Shaji K. Kumar
ResearchOpen Access27 Feb 2025
Leukemia

Volume: 39, P: 942-950
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

Hartmut Goldschmidt
Elias K. Mai
Hans J. Salwender
Research07 Feb 2020
Leukemia

Volume: 34, P: 1853-1865
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Molly Went
Amit Sud
Richard S. Houlston
Amendments and CorrectionsOpen Access10 Jan 2019
Nature Communications

Volume: 10, P: 1-3
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

Katja C. Weisel
Christof Scheid
Hartmut Goldschmidt
ResearchOpen Access08 Apr 2019
Blood Cancer Journal

Volume: 9, P: 1-4
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study

Philippe Moreau
Thierry Facon
Shaji K. Kumar
Research15 Jan 2025
Leukemia

Volume: 39, P: 710-719
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma

Nora Grieb
Alexander Oeser
Maximilian Merz
ResearchOpen Access05 Dec 2024
Bone Marrow Transplantation

Volume: 60, P: 335-345
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

Lisa B. Leypoldt
Britta Besemer
Katja C. Weisel
ResearchOpen Access03 Nov 2021
Leukemia

Volume: 36, P: 885-888
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk

Richard Houlston, Gareth Morgan, Kari Hemminki and colleagues report the results of a genome-wide association study of multiple myeloma. They identify two regions influencing susceptibility to this hematological malignancy.

Peter Broderick
Daniel Chubb
Richard S Houlston
Research27 Nov 2011
Nature Genetics

Volume: 44, P: 58-61
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

Elias K. Mai
Kaya Miah
Hartmut Goldschmidt
ResearchOpen Access20 Jul 2020
Leukemia

Volume: 35, P: 809-822
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Marc-Andrea Baertsch
Elias K. Mai
Hartmut Goldschmidt
ResearchOpen Access07 Jan 2021
Blood Cancer Journal

Volume: 11, P: 1-10
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

María-Victoria Mateos
Katja Weisel
Philippe Moreau
ResearchOpen Access25 Sept 2024
Leukemia

Volume: 38, P: 2554-2560
Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance

Hauke Thomsen
Subhayan Chattopadhyay
Asta Försti
ResearchOpen Access20 Aug 2024
Blood Cancer Journal

Volume: 14, P: 1-12
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

Hans Salwender
Ahmet Elmaagacli
Hartmut Goldschmidt
Research24 May 2021
Leukemia

Volume: 35, P: 3007-3011
Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma

Hauke Thomsen
Subhayan Chattopadhyay
Asta Försti
Research08 Feb 2019
Leukemia

Volume: 33, P: 1817-1821
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

Elias K. Mai
Thomas Hielscher
Hartmut Goldschmidt
Research29 Jun 2018
Leukemia

Volume: 33, P: 258-261
Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma

Maximilian Merz
Thomas Hielscher
Hartmut Goldschmidt
ResearchOpen Access11 Nov 2019
Leukemia

Volume: 34, P: 1192-1196
Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance

Subhayan Chattopadhyay
Hauke Thomsen
Asta Försti
Research06 Nov 2019
Leukemia

Volume: 34, P: 1187-1191
Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma

Elena Viziteu
Camille Grandmougin
Jerome Moreaux
ResearchOpen Access11 Feb 2016
British Journal of Cancer

Volume: 114, P: 519-523
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Elias K. Mai
Thomas Hielscher
Hartmut Goldschmidt
ResearchOpen Access07 Dec 2023
Leukemia

Volume: 38, P: 640-647
High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders

Sebastian Köhrer
Tobias Dittrich
Alwin Krämer
ResearchOpen Access11 Oct 2023
Leukemia

Volume: 37, P: 2468-2478
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma

Annika Werly
Mareike Hampel
Elias K. Mai
CorrespondenceOpen Access14 Oct 2024
Blood Cancer Journal

Volume: 14, P: 1-4
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Elias K. Mai
Stefanie Huhn
Niels Weinhold
ResearchOpen Access04 Jan 2023
Blood Cancer Journal

Volume: 13, P: 1-9
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

Thierry Facon
Gordon Cook
Sonja Zweegman
ResearchOpen Access02 Jan 2022
Leukemia

Volume: 36, P: 1066-1077
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Maria-Victoria Mateos
Katja Weisel
Philippe Moreau
ResearchOpen Access24 Mar 2022
Leukemia

Volume: 36, P: 1371-1376
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

Maximilian Merz
Thomas Hielscher
Jens Hillengass
CorrespondenceOpen Access27 Aug 2019
Blood Cancer Journal

Volume: 9, P: 1-5

Previous page
page 1
page 2
Next page

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Italy
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

© 2025 Springer Nature Limited